Correction to: COVID-19 biomarkers for severity mapped to polycystic ovary syndrome

Affiliations

¹ Diabetes Research Center (DRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, Qatar.
² Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK.
³ Royal College of Surgeons in Ireland Bahrain, Adliya, Kingdom of Bahrain.
⁴ Diabetes Research Center (DRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, Qatar. aeb91011@gmail.com.

^# Contributed equally.

Published Erratum

Abu Saleh Md Moin et al. J Transl Med. 2021.

. 2021 Mar 15;19(1):106.

doi: 10.1186/s12967-021-02782-w.

¹ Diabetes Research Center (DRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, Qatar.
² Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK.
³ Royal College of Surgeons in Ireland Bahrain, Adliya, Kingdom of Bahrain.
⁴ Diabetes Research Center (DRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), PO Box 34110, Doha, Qatar. aeb91011@gmail.com.

^# Contributed equally.

No abstract available

Erratum for

COVID-19 biomarkers for severity mapped to polycystic ovary syndrome.
Moin ASM, Sathyapalan T, Atkin SL, Butler AE. Moin ASM, et al. J Transl Med. 2020 Dec 22;18(1):490. doi: 10.1186/s12967-020-02669-2. J Transl Med. 2020. PMID: 33353554 Free PMC article. No abstract available.

1. Moin ASM, Sathyapalan T, Atkin SL, Butler AE. COVID-19 biomarkers for severity mapped to polycystic ovary syndrome. J Transl Med. 2020;18:490. doi: 10.1186/s12967-020-02669-2. - DOI - PMC - PubMed